EMA Authorised: Camzyos (Mavacamten) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Camzyos (mavacamten) for hypertrophic cardiomyopathy, with Bristol-Myers Squibb Pharma EEIG as the marketing authorizat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• CAMZYOS (MAVACAMTEN)

Snippet

Status: Authorised. Therapeutic area: Cardiomyopathy, Hypertrophic. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 30/05/2025